Teva Pharmaceutical Industries Limited (TEVJF)

OTCMKTS · Delayed Price · Currency is USD
28.36
-4.48 (-13.64%)
At close: Jan 26, 2026
Market Cap39.16B +105.2%
Revenue (ttm)17.26B +4.3%
Net Income1.41B
EPS1.21
Shares Outn/a
PE Ratio27.77
Forward PE12.46
Dividendn/a
Ex-Dividend Daten/a
Volume130
Average Volume425
Open28.36
Previous Close32.84
Day's Range28.36 - 28.36
52-Week Range13.73 - 32.84
Beta0.72
RSI63.14
Earnings DateJan 28, 2026

About TEVJF

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 32,842
Stock Exchange OTCMKTS
Ticker Symbol TEVJF
Full Company Profile

Financial Performance

Financial Statements

News

Teva to Present at the Upcoming Investor Conferences in March

PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will ...

1 day ago - GlobeNewsWire

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) on Friday announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injec...

2 days ago - Benzinga

Teva (TEVA) Advances Schizophrenia Treatment with FDA Application

Teva (TEVA) Advances Schizophrenia Treatment with FDA Application

4 days ago - GuruFocus

FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment

(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its...

5 days ago - Nasdaq

Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application

Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application

5 days ago - GuruFocus

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...

5 days ago - GlobeNewsWire

Price Over Earnings Overview: Teva Pharmaceutical Indus

In the current market session, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock price is at $34.97, after a 2.32% drop. However, over the past month, the company's stock went up by 5.42% , and in th...

5 days ago - Benzinga

Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

6 days ago - Seeking Alpha

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Corcept Therapeutics shares plunged Thursday morning after a federal appeals court upheld a ruling that Teva Pharmaceuticals' proposed generic does not infringe two Korlym-related patents. ... Full st...

6 days ago - Benzinga

Corcept falls as appeals court sides with Teva in Korlym patent dispute

Corcept Therapeutics (CORT) stock plunged after an appeals court backed Teva (TEVA) in a patent dispute over the company's lead drug Korlym. Read more here.

6 days ago - Seeking Alpha

Truist Securities Raises Price Target for TEVA, Maintains Buy Rating | TEVA Stock News

Truist Securities Raises Price Target for TEVA, Maintains Buy Rating | TEVA Stock News

7 days ago - GuruFocus

Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow

2026-02-17. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with this event.

8 days ago - Seeking Alpha

Sanofi, Teva Report Positive Phase 2b Results For Duvakitug

(RTTNews) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerative coliti...

8 days ago - Nasdaq

Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) will hold an investor call and webcast today to highlight new Phase 2b maintenance data for Duvakitug. The investigational thera...

8 days ago - Nasdaq

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study. Positive Data Fr...

9 days ago - Benzinga

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Teva and Sanofi SA (NASDAQ: SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.

9 days ago - Benzinga

Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's

Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's

9 days ago - GuruFocus

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tole...

9 days ago - Benzinga

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug sh...

9 days ago - Benzinga

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.

9 days ago - GlobeNewsWire

Harel Insurance Investments & Financial Services Ltd. ...

Harel Insurance Investments & Financial Services Ltd. Increases Stake in Teva Pharmaceutical Industries Ltd.

12 days ago - GuruFocus

Noteworthy ETF Inflows: SPDW, SPOT, SE, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...

14 days ago - Nasdaq